Peanut-specific immunoglobulin E (Peanut-specific IgE)

Peanut-specific immunoglobulin E (IgE) is the central mediator of peanut allergy, a potent Type I hypersensitivity reaction. These antibodies are generated against specific peanut proteins, primarily Ara h 1, Ara h 2, and Ara h 3, and reside on the surface of mast cells and basophils by binding to the high-affinity FcεRI receptor (NIH, 2023). Upon allergen exposure, the cross-linking of IgE-FcεRI complexes triggers the rapid release of inflammatory mediators like histamine and leukotrienes, which can lead to life-threatening anaphylaxis (StatPearls, 2023). Therapeutic strategies targeting this axis include the monoclonal antibody omalizumab, which sequesters free IgE to prevent receptor loading, and oral immunotherapy (OIT) like Palforzia, which aims to induce clinical desensitization by modulating the IgE/IgG4 ratio (FDA, 2024). Additionally, downstream effectors are targeted by emerging therapies such as BTK inhibitors, which block the signaling cascade initiated by IgE-receptor cross-linking (Journal of Allergy and Clinical Immunology, 2022). Monitoring peanut-specific IgE levels, particularly those directed against the Ara h 2 component, serves as a critical biomarker for diagnosing allergy severity and predicting the likelihood of clinical reactions (PubMed, 2021).

Other names

Peanut-specific IgEAra h-specific IgEAllergen-specific IgEAnti-peanut IgE

The primary mechanism of action for drugs targeting this pathway involves the sequestration of free peanut-specific IgE by monoclonal antibodies (e.g., omalizumab), which prevents its binding to the high-affinity FcεRI receptors on mast cells and basophils, leading to a reduction in effector cell sensitivity (FDA, 2024). Immunotherapies work by gradually exposing the patient to peanut proteins to shift the immune profile from a Th2-mediated IgE response to a Th1/Treg-mediated response characterized by increased IgG4 "blocking" antibodies (NIH, 2023). Downstream signaling can also be inhibited by small molecules like BTK inhibitors that prevent the degranulation of mast cells and basophils following IgE-receptor cross-linking (Journal of Allergy and Clinical Immunology, 2022).